Rimegepant (NURTEC ODT), approved by FDA in February 2020, is a medication for the treatment of acute migraine in adults. It is a potent, selective, competitive and orally active antagonist of calcitonin gene-related peptide (CGRP). Part of this molecule contains a fused cycloheptane-pyridine amine fragment. We have created a set of Building Blocks, which contains similar moieties, to generate new ideas for your projects.